Depression

What it is

Depression — clinically, major depressive disorder — is a mood disorder defined by episodes of persistently low mood and/or a loss of interest and pleasure, lasting at least two weeks and accompanied by a cluster of emotional, physical, and cognitive changes that cause real distress or impairment. It is not ordinary sadness, and it is not a passing mood; it is a sustained shift in how a person feels, thinks, sleeps, eats, moves, and functions. It is also one of the most common and disabling health conditions in the world.

A clinically diagnosed depressive episode requires several symptoms occurring together most of the day, nearly every day: depressed mood; markedly reduced interest or pleasure (anhedonia); changes in appetite or weight; disturbed sleep; slowed or agitated movement; fatigue or loss of energy; feelings of worthlessness or excessive guilt; difficulty concentrating or deciding (brain fog); and recurrent thoughts of death or suicide. At least one of the first two — low mood or lost pleasure — must be present. The diagnosis, in other words, is the symptoms occurring together as a syndrome.

A crucial early point: depression is a syndrome, not a single biological disease. Two people with the same diagnosis can have almost no symptoms in common, which shapes everything from research to treatment.

Subtypes and specifiers

Because depression is heterogeneous, clinicians describe it further with specifiers that often carry biological and treatment significance:

Melancholic depression features pervasive, non-reactive loss of pleasure, early-morning waking, weight loss, marked slowing or agitation, and excessive guilt — the more "classical, biological" picture. Atypical depression, by contrast, features mood that still brightens with good events, increased appetite and sleep, a heavy "leaden" feeling in the limbs, and sensitivity to rejection — a pattern that maps onto inflammatory-metabolic biology. Psychotic depression adds delusions or hallucinations and is severe, requiring specific treatment. Other specifiers include anxious distress, mixed features (depressive episodes carrying some manic-type symptoms — an important warning sign for bipolarity), peripartum onset (around childbirth), seasonal pattern (recurring in winter), and catatonia.

Related diagnoses on the depressive spectrum include persistent depressive disorder (dysthymia), a chronic, lower-grade depression lasting two years or more, and treatment-resistant depression, the term used when two or more adequate treatments have failed.

How common, and who

Depression is among the most prevalent psychiatric conditions, with a lifetime risk in the range of 15–20% and roughly 7% of adults affected in any given year. It is about twice as common in women as in men, though it may be under-recognized in men, where it can present more as irritability, withdrawal, or substance use. It can begin at any age but often first appears in the late teens and twenties. Globally, it is a leading cause of disability — a major driver of lost function, not just of personal suffering.

What causes it

There is no single cause. Depression arises from the interaction of genetic vulnerability, biological processes, and life circumstances. Heritability is moderate (around 35–40%) and highly polygenic, spread across many genes of tiny effect rather than any single "depression gene." Stressful life events, and especially early-life adversity, raise risk substantially. Biologically, the field has moved beyond the old "chemical imbalance" story (see the controversies below) toward a convergence model in which many routes — inflammation, HPA-axis and chronic stress, metabolic and circadian disturbance — funnel toward a common downstream disruption of neuroplasticity. The honest summary is that depression is best understood as a final common pathway reachable by many different upstream roads.

How it is diagnosed

Depression is diagnosed clinically — through history and interview — because there is no blood test, scan, or genetic test that can confirm or exclude it. Brief questionnaires such as the PHQ-9 help screen and track severity, but the diagnosis rests on clinical assessment.

The most important task in that assessment is the differential — making sure the depression is what it appears to be. The single most consequential distinction is from bipolar disorder: because most people with bipolar disorder first seek help during a depressive episode, every depressed patient should be asked about past periods of elevated or unusually energized mood, since missing a bipolar diagnosis and treating with an antidepressant alone can do harm. Clinicians also rule out medical contributors (thyroid disease, anemia, vitamin B12 deficiency, certain medications, neurological conditions), substance-induced mood changes, and they distinguish depression from normal grief and from adjustment to difficult circumstances — recognizing that the boundary is genuinely blurry.

Course and prognosis

Depression is typically episodic and recurrent. An untreated episode often lasts six months to a year, and more than half of people who have one episode will have another, with risk rising after each. A meaningful minority develop a chronic course. With treatment the outlook is generally good, but two realities deserve emphasis. First, residual symptoms — lingering fatigue, cognitive difficulty, anhedonia, or sleep disturbance after mood improves — are common and predict relapse, which is why treatment aims at full remission rather than mere improvement. Second, depression carries a real risk of suicide, making assessment of safety an essential, ongoing part of care.

Treatment

The treatment landscape is broad, and effective care usually means matching the approach to the person and persisting until remission.

Psychotherapy is first-line for mild-to-moderate depression and effective across the range. Cognitive behavioral therapy, behavioral activation (which directly targets the withdrawal and anhedonia), and interpersonal therapy have the strongest evidence, among others.

Medication is a mainstay for moderate-to-severe depression. SSRIs are usually first-line, with SNRIs, bupropion, mirtazapine, and others as alternatives, and older agents (tricyclics, MAO inhibitors) still valuable in specific situations. An honest caveat from the landmark STAR*D study: only about a third of patients remit on the first medication, and finding the right treatment is often a sequential process. When standard options fail, augmentation strategies (lithium, certain antipsychotics, thyroid hormone) and rapid-acting treatments — ketamine and esketamine — come into play.

Neuromodulation offers the most effective option for severe, psychotic, or treatment-resistant depression: ECT remains the most effective acute treatment, with TMS a well-tolerated non-invasive alternative. Lifestyle and adjunctive measures — exercise (which has reasonable evidence), sleep and circadian regulation, and bright light for seasonal depression — round out care.

An emerging theme is matching treatment to subtype and symptom: dopamine-oriented strategies for prominent anhedonia, attention to inflammation in the immunometabolic subtype, CBT-I for the insomnia component. This stratified approach is the rational future of depression care, even if it is not yet routine.

Controversies and honest caveats

Depression is surrounded by genuine, unsettled debates worth understanding. The "chemical imbalance" account — that depression is simply a serotonin deficiency — is not well supported by the evidence (a widely discussed umbrella review by Moncrieff and colleagues made this case forcefully); importantly, this does not mean antidepressants don't work, only that their benefit is not explained by correcting a known deficiency. The efficacy of antidepressants is itself debated: their average advantage over placebo is modest and is larger in more severe depression, a nuance often lost in both marketing and criticism. There are real concerns about over-diagnosis in some settings and under-treatment in others, about discontinuation effects when stopping antidepressants, and about the heterogeneity that makes "depression" a loose container for biologically different conditions. None of this means depression isn't real or treatable — it is both — but the science is more honest and more uncertain than simple slogans suggest.

Bottom line

Depression is a common, recurrent, and genuinely disabling mood disorder — a syndrome in which low mood and lost pleasure travel with characteristic changes in sleep, appetite, energy, movement, thinking, and self-worth. It is best understood not as a single chemical fault but as a final common pathway reached by many routes, which is why it varies so much between people and why treatment so often must be matched and sequential. It is diagnosed clinically, with the distinction from bipolar disorder the most important to get right, and it is treated through a broad toolkit — psychotherapy, medication, neuromodulation, and lifestyle change — aimed at full remission, because the symptoms left behind are the ones that bring it back. The encouraging reality beneath the honest uncertainties is that depression responds to treatment for most people, especially when care is persistent, comprehensive, and tailored.

Selected references

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed (DSM-5-TR). 2022.
2. Otte C, et al. Major depressive disorder. Nat Rev Dis Primers. 2016.
3. Malhi GS, Mann JJ. Depression. Lancet. 2018.
4. Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annu Rev Public Health. 2013.
5. GBD 2019 Mental Disorders Collaborators. Global burden of mental disorders. Lancet Psychiatry. 2022.
6. Rush AJ, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps (STAR*D). Am J Psychiatry. 2006.
7. Cipriani A, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018.
8. Cuijpers P, et al. Psychotherapy for depression across different age groups and treatment formats: a network meta-analysis. World Psychiatry. 2021.
9. Moncrieff J, et al. The serotonin theory of depression: a systematic umbrella review of the evidence. Mol Psychiatry. 2022.
10. Kirsch I, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the FDA. PLoS Med. 2008.
11. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry. 2000.
12. Hasin DS, et al. Epidemiology of adult DSM-5 major depressive disorder. JAMA Psychiatry. 2018.
13. Trivedi MH, et al. Evaluation of outcomes with citalopram for depression using measurement-based care. Am J Psychiatry. 2006.
14. Kennedy SH, et al. CANMAT clinical guidelines for the management of adults with major depressive disorder. Can J Psychiatry. 2016.
15. Jick H, et al. Antidepressants and the risk of suicidal behaviors. JAMA. (suicide-risk literature.)
16. Geddes JR, et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003.
17. Vittengl JR, et al. Reducing relapse and recurrence in unipolar depression. J Consult Clin Psychol. 2007.
18. World Health Organization. Depressive disorder (depression) fact sheet. 2023.